Published in Anticancer Res on December 07, 2005
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. Br J Cancer (2007) 0.81
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. J Cancer Res Clin Oncol (2010) 0.80
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study. J Cancer Res Clin Oncol (2014) 0.75
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst (2007) 2.42
Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat (2010) 1.97
Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer (2012) 1.05
Comparison of short- and medium-term results between laparoscopically assisted and totally laparoscopic right hemicolectomy: a case-control study. Surg Endosc (2010) 0.96
Pain and its treatment in hospitalized patients with metastatic cancer. Support Care Cancer (2003) 0.95
Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res (2007) 0.92
Alkaline phosphatase levels as a prognostic factor in metastatic colorectal cancer treated with the FOLFOX 4 regimen: a monoinstitutional retrospective study. Tumori (2011) 0.89
Laparoscopic resection of duodenal gangliocytic paraganglioma. A case report. Chir Ital (2007) 0.85
Mucinous histology of colon cancer predicts poor outcomes with FOLFOX regimen in metastatic colon cancer. J Chemother (2012) 0.85
Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. Cancer Biol Ther (2009) 0.83
Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. Breast Cancer Res Treat (2011) 0.82
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. Oncology (2013) 0.82
Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) (2012) 0.81
Immunohistochemically defined subtypes and outcome of apocrine breast cancer. Clin Breast Cancer (2012) 0.81
Current knowledge and future directions on bisphosphonate-related osteonecrosis of the jaw in cancer patients. Expert Opin Pharmacother (2008) 0.81
Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer. Breast Cancer Res Treat (2015) 0.80
Timing of adjuvant systemic therapy and radiotherapy after breast-conserving surgery and mastectomy. Cancer Treat Rev (2010) 0.80
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reports. Cancer Biol Ther (2012) 0.80
The role of ultrasound-guided aspiration biopsy of peripheral pulmonary nodules: our experience. Anticancer Res (2002) 0.78
Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer. Lung Cancer (2009) 0.76
Long-term survival in locally advanced oral cavity cancer: an analysis of patients treated with neoadjuvant cisplatin-based chemotherapy followed by surgery. Head Neck (2005) 0.76
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol (2011) 0.76
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel. J Cardiovasc Pharmacol (2013) 0.76
Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? Anticancer Res (2003) 0.75
High-dose chemotherapy with mitoxantrone + melphalan and autologous stem cell rescue in metastatic breast cancer patients: a study of feasibility and tolerability. Tumori (2004) 0.75
Mitomycin C plus capecitabine (mixe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study. Anticancer Res (2007) 0.75
[Laparoscopy in abdominal emergencies. Indications and limitations]. Chir Ital (2002) 0.75